Pompe Disease: From Basic Science to TherapyElsevier BV - Tập 15 - Trang 928-942 - 2018
Lara Kohler, Rosa Puertollano, Nina Raben
Pompe disease is a rare and deadly muscle disorder. As a clinical entity, the disease has been known for over 75 years. While an optimist might be excited about the advances made during this time, a pessimist would note that we have yet to find a cure. However, both sides would agree that many findings in basic science—such as the Nobel prize-winning discoveries of glycogen metabolism, the lysosom...... hiện toàn bộ
Dual HDAC/BRD4 Inhibitors Relieves Neuropathic Pain by Attenuating Inflammatory Response in Microglia After Spared Nerve InjuryElsevier BV - Tập 19 - Trang 1634-1648 - 2022
Vittoria Borgonetti, Elisabetta Meacci, Federica Pierucci, Maria Novella Romanelli, Nicoletta Galeotti
Despite the effort on developing new treatments, therapy for neuropathic pain is still a clinical challenge and combination therapy regimes of two or more drugs are often needed to improve efficacy. Accumulating evidence shows an altered expression and activity of histone acetylation enzymes in chronic pain conditions and restoration of these aberrant epigenetic modifications promotes pain-relievi...... hiện toàn bộ
The Use of Pharmacological Retromer Chaperones in Alzheimer’s Disease and other Endosomal-related DisordersElsevier BV - Tập 12 - Trang 12-18 - 2014
Diego E. Berman, Dagmar Ringe, Greg A. Petsko, Scott A. Small
The retromer is an evolutionary conserved multiprotein complex involved in the sorting and retrograde trafficking of cargo from endosomal compartments to the Golgi network and to the cell surface. The neuronal retromer traffics the amyloid precursor protein away from the endosomes, a site where amyloid precursor protein is enzymatically cleaved into pathogenic fragments in Alzheimer’s disease. In ...... hiện toàn bộ
Betulinic Acid Hydroxamate is Neuroprotective and Induces Protein Phosphatase 2A-Dependent HIF-1α Stabilization and Post-transcriptional Dephosphorylation of Prolyl Hydrolase 2Elsevier BV - Tập 18 - Trang 1849-1861 - 2021
María E. Prados, Alejandro Correa-Sáez, Juan D. Unciti-Broceta, Martín Garrido-Rodríguez, Carla Jimenez-Jimenez, Massimiliano Mazzone, Alberto Minassi, Giovanni Appendino, Marco A. Calzado, Eduardo Muñoz
Huntington’s disease (HD) is a neurodegenerative disorder characterized by unwanted choreatic movements, behavioral and psychiatric disturbances, and dementia. The activation of the hypoxic response pathway through the pharmacological inhibition of hypoxia-inducing factor (HIF) prolyl-hydroxylases (PHDs) is a promising approach for neurodegenerative diseases, including HD. Herein, we have studied ...... hiện toàn bộ
Targeting Mitochondrial Function for the Treatment of Acute Spinal Cord InjuryElsevier BV - Tập 8 - Trang 168-179 - 2011
Melanie L. McEwen, Patrick G. Sullivan, Alexander G. Rabchevsky, Joe E. Springer
Traumatic injury to the mammalian spinal cord is a highly dynamic process characterized by a complex pattern of pervasive and destructive biochemical and pathophysiological events that limit the potential for functional recovery. Currently, there are no effective therapies for the treatment of spinal cord injury (SCI) and this is due, in part, to the widespread impact of the secondary injury casca...... hiện toàn bộ
Molecular Tweezers Targeting Transthyretin AmyloidosisElsevier BV - Tập 11 - Trang 450-461 - 2014
Nelson Ferreira, Alda Pereira-Henriques, Aida Attar, Frank-Gerrit Klärner, Thomas Schrader, Gal Bitan, Luís Gales, Maria João Saraiva, Maria Rosário Almeida
Transthyretin (TTR) amyloidoses comprise a wide spectrum of acquired and hereditary diseases triggered by extracellular deposition of toxic TTR aggregates in various organs. Despite recent advances regarding the elucidation of the molecular mechanisms underlying TTR misfolding and pathogenic self-assembly, there is still no effective therapy for treatment of these fatal disorders. Recently, the “m...... hiện toàn bộ
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS StudyElsevier BV - Tập 19 - Trang 1248-1258 - 2022
Michael Benatar, Joanne Wuu, Peter M. Andersen, Robert C. Bucelli, Jinsy A. Andrews, Markus Otto, Nita A. Farahany, Elizabeth A. Harrington, Weiping Chen, Adele A. Mitchell, Toby Ferguson, Sheena Chew, Liz Gedney, Sue Oakley, Jeong Heo, Sowmya Chary, Laura Fanning, Danielle Graham, Peng Sun, Yingying Liu, Janice Wong, Stephanie Fradette
Despite extensive research, amyotrophic lateral sclerosis (ALS) remains a progressive and invariably fatal neurodegenerative disease. Limited knowledge of the underlying causes of ALS has made it difficult to target upstream biological mechanisms of disease, and therapeutic interventions are usually administered relatively late in the course of disease. Genetic forms of ALS offer a unique opportun...... hiện toàn bộ
The Current Landscape of Prevention Trials in DementiaElsevier BV - Tập 19 - Trang 228-247 - 2022
Jonathan Lee, Rebecca Sitra Howard, Lon S. Schneider
As the prevalence of dementia and Alzheimer’s disease (AD) increases worldwide, it is imperative to reflect on the major clinical trials in the prevention of dementia and the challenges that surround them. The pharmaceutical industry has focused on developing drugs that primarily affect the Aβ cascade and tau proteinopathy, while academics have focused on repurposed therapeutics and multi-domain i...... hiện toàn bộ
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating StudyElsevier BV - Tập 18 - Trang 1127-1136 - 2021
Stacy A. Rudnicki, Jinsy A. Andrews, Tina Duong, Bettina M. Cockroft, Fady I. Malik, Lisa Meng, Jenny Wei, Andrew A. Wolff, Angela Genge, Nicholas E. Johnson, Carolina Tesi-Rocha, Anne M. Connolly, Basil T. Darras, Kevin Felice, Richard S. Finkel, Perry B. Shieh, Jean K. Mah, Jeffrey Statland, Craig Campbell, Ali A. Habib, Nancy L. Kuntz, Maryam Oskoui, John W. Day
This phase 2, double-blind, placebo-controlled, hypothesis-generating study evaluated the effects of oral reldesemtiv, a fast skeletal muscle troponin activator, in patients with spinal muscular atrophy (SMA). Patients ≥ 12 years of age with type II, III, or IV SMA were randomized into 2 sequential, ascending reldesemtiv dosing cohorts (cohort 1: 150 mg bid or placebo [2:1]; cohort 2: 450 mg bid o...... hiện toàn bộ